Clinical Trial

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-15
critical Primary endpoint(s) modified 2026-07-07
minor Trial arms changed: 1 -> 4 2026-07-07
minor Completion pushed: 2026-06-30 -> 2027-06-30 2026-07-07
Trial Details
NCT Number NCT03742895
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: AstraZeneca
Conditions Advanced Solid Neoplasms
Enrollment 329 participants
Start Date 2018-12-12
Primary Completion 2025-08-12 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14